News

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to…

2 years ago

Sernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the Med

LONDON, Ontario, April 10, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell…

2 years ago

StateHouse Celebrates California Cannabis With ‘Bay To Border’ Activations

California-focused cannabis enterprise celebrates 4/20 by reaffirming commitment to communities throughout the Golden StateSAN DIEGO and TORONTO, April 10, 2023…

2 years ago

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

— Presentation entitled "BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility" — — First-in-human Phase 1 trial for lead program,…

2 years ago

CloudMD Names Dhruv Chandra Chief Technology Officer to Accelerate Technological Advancement in Next Phase of Growth

CloudMD strengthens its commitment to innovation, exceptional customer experiences, data-driven insights, security, and complianceVANCOUVER, British Columbia, April 10, 2023 (GLOBE…

2 years ago

Mainz Biomed Provides Full Year 2022 Financial Results

ColoAlert Revenue Increases 130% Year over Year Year End Cash Balance of $17.1 Million BERKELEY, Calif. and MAINZ, Germany, April…

2 years ago

OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy

Poster Presentations to highlight the latest research on OBI-999’s (anti-Globo H ADC) synergistic anti-tumor effect in combination with pembrolizumab and…

2 years ago

Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD

LONDON and RALEIGH, N.C., April 10, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”),…

2 years ago

Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169

Partial hold based on previously disclosed cardiac events at 50 mcg/kg cohort; FDA to review safety data in lower dose…

2 years ago